Interleukin Genetics, Inc., Q1 2013 Earnings Call, May 23, 2013

Interleukin Genetics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2012. For the quarter, the company reported net loss of $1,189,319 or $0.03 per basic and diluted share on total revenue was $339,057 against net loss of $1,422,662 or $0.04 per basic and diluted share on total revenue was $575,339 a year ago. Loss from operations was $1,073,289 compared to $1,324,196 a year ago. Loss from continuing operations before income taxes was $1,189,319 compared to $1,422,662 a year ago. Loss from continuing operations was $1,189,319 or $0.03 per basic and diluted share compared to loss from continuing operations was $1,422,662 or $0.04 per basic and diluted share a year ago. The decrease in revenue is primarily attributable to decreased genetic testing revenue as a result of sales through the Amway Global sales channel. For the full year, the company reported net loss of $5,120,084 or $0.14 per basic and diluted share on total revenue was $2,236,387 against net loss of $5,025,182 or $0.14 per basic and diluted share on total revenue was $2,857,105 a year ago. Loss from operations was $4,670,088 compared to $4,827,303 a year ago. Loss from continuing operations before income taxes was $5,120,084 compared to $5,183,548 a year ago. Loss from continuing operations was $5,120,084 or $0.14 per basic and diluted share compared to loss from continuing operations was $5,183,548 or $0.14 per basic and diluted share a year ago. The revenue decrease is primarily attributable to decreased sales of the company's Inherent Health(R) brand of genetic tests through the Amway Global sales channel. The company expects to incur additional losses in 2013.

On March 27, 2013, Interleukin Genetics, Inc. announced that Thomas R. Curran, Jr. was resigning as a director of the company and as a member of all committees of the company’s Board of Directors on which he serves, effective as of the close of business on March 28, 2013. Mr. Curran served as a designee elected by the holder of the Company’s Series A-1 Convertible Preferred Stock and served on the Company’s Audit Committee and Compensation Committee. Goran Jurcuvic has been appointed by the Board to fill the vacancy on the Audit Committee.